<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39384643</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1573-2592</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>10</Day></PubDate></JournalIssue><Title>Journal of clinical immunology</Title><ISOAbbreviation>J Clin Immunol</ISOAbbreviation></Journal><ArticleTitle>Novel Compound Heterozygous Variants in the FAS Gene Lead to Fetal Onset of Autoimmune Lymphoproliferative Syndrome (ALPS).</ArticleTitle><Pagination><StartPage>23</StartPage><MedlinePgn>23</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10875-024-01812-8</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">FAS gene defects lead to autoimmune lymphoproliferative syndrome (ALPS), which is often inherited in an autosomal dominant and rarely in an autosomal recessive manner. We report a case of a newborn girl with novel compound heterozygous variants in FAS and reveal the underlying mechanism.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Whole-exome sequencing (WES) was used to identify pathogenic variants. Multiparametric flow cytometry analysis, phosflow analysis, and FAS-induced apoptosis assays were used to explore the effects of the variants on FAS expression, apoptosis, and immunophenotype. The HEK293T cells were used to assess the impact of the variants on protein expression and FAS-induced apoptosis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The patient was born with hepatosplenomegaly, anemia, and thrombocytopenia. She also experienced COVID-19, rotavirus infection, herpes simplex virus infection, and severe pneumonia. The proportion of double-negative T cells (DNTs) was significantly elevated. Novel FAS compound heterozygous variants c.310T &gt; A (p.C104S) and c.702_704del (p.T235del) were identified. The apoptotic ability of T cells was defective, and FAS expression on the surface of T cells was deficient. The T235del variant decreased FAS expression, and the C104S protein remained in the endoplasmic reticulum (ER) and could not translocate to the cell surface. Both mutations resulted in loss-of-function in terms of FAS-induced apoptosis in HEK293T cells. The DNTs were mainly terminally differentiated T (TEMRA) and CD45RA<sup>+</sup>HLA-DR<sup>+</sup>, with high expression of CD85j, PD-1, and CD57. The percentage of Th1, Tfh, and autoreactive B cells were significantly increased in the patient. The abnormal immunophenotyping was partially attenuated by sirolimus treatment.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We identified two variants that significantly affect FAS expression or localization, leading to early disease onset of in the fetus. Abnormalities in the mTOR pathway are associated with a favorable response to sirolimus.</AbstractText><CopyrightInformation>© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Wu</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Allergy and Clinical Immunology, Children's Hospital of Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Sun</LastName><ForeName>Bijun</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Allergy and Clinical Immunology, Children's Hospital of Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Jia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Allergy and Clinical Immunology, Children's Hospital of Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hui</LastName><ForeName>Xiaoying</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Allergy and Clinical Immunology, Children's Hospital of Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chenghao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Allergy and Clinical Immunology, Children's Hospital of Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wenjie</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Allergy and Clinical Immunology, Children's Hospital of Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ying</LastName><ForeName>Wenjing</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Allergy and Clinical Immunology, Children's Hospital of Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Luyao</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Allergy and Clinical Immunology, Children's Hospital of Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neonatology, Children's Hospital of Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Key Laboratory of Neonatal Diseases, Ministry of Health, Children's Hospital of Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qifan</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Allergy and Clinical Immunology, Children's Hospital of Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Meiping</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Allergy and Clinical Immunology, Children's Hospital of Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Weitao</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Children's Hospital of Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Children's Hospital of Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Bingbing</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Clinical Genetic Center, Children's Hospital of Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Jinqiao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Allergy and Clinical Immunology, Children's Hospital of Fudan University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Qinhua</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Allergy and Clinical Immunology, Children's Hospital of Fudan University, Shanghai, China. qinhua_zhou@fudan.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Ministry of Education Key Laboratory of Contemporary Anthropology, Human Phenome Institute, School of Life Sciences, Fudan University, Shanghai, China. fengqian@fudan.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaochuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Allergy and Clinical Immunology, Children's Hospital of Fudan University, Shanghai, China. xchwang@shmu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanghai Institute of Infectious Disease and Biosecurity, Shanghai, China. xchwang@shmu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>23YF1403400</GrantID><Agency>"Sailing Program" of Shanghai Science and Technology Committee</Agency><Country /></Grant><Grant><GrantID>23DZ2202600</GrantID><Agency>Shanghai Municipal Technology Standards Project</Agency><Country /></Grant><Grant><GrantID>2023SHZDZX02, 2017SHZDZX01</GrantID><Agency>Shanghai Municipal Science and Technology Major Project</Agency><Country /></Grant><Grant><GrantID>ZD2021CY001</GrantID><Agency>Shanghai Municipal Science and Technology Major Project</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Clin Immunol</MedlineTA><NlmUniqueID>8102137</NlmUniqueID><ISSNLinking>0271-9142</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019014">fas Receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C491901">FAS protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056735" MajorTopicYN="Y">Autoimmune Lymphoproliferative Syndrome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019014" MajorTopicYN="Y">fas Receptor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073359" MajorTopicYN="Y">Exome Sequencing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="Y">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FAS</Keyword><Keyword MajorTopicYN="N">Apoptosis</Keyword><Keyword MajorTopicYN="N">Autoimmune Lymphoproliferation Syndrome</Keyword><Keyword MajorTopicYN="N">Compound heterozygous mutations</Keyword><Keyword MajorTopicYN="N">Double-negative T Cells</Keyword><Keyword MajorTopicYN="N">Immunophenotyping</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>0</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>0</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>23</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39384643</ArticleId><ArticleId IdType="doi">10.1007/s10875-024-01812-8</ArticleId><ArticleId IdType="pii">10.1007/s10875-024-01812-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Canale VC, Smith CH. Chronic lymphadenopathy simulating malignant lymphoma. J Pediatr. 1967;70:891–9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-3476(67)80262-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Rieux-Laucat F, Magérus-Chatinet A, Neven B. The autoimmune lymphoproliferative syndrome with defective FAS or FAS-Ligand functions. J Clin Immunol. 2018;38:558–68.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-018-0523-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Magerus A, Bercher-Brayer C, Rieux-Laucat F. The genetic landscape of the FAS pathway deficiencies. Biomed J. 2021;44:388–99.</Citation><ArticleIdList><ArticleId IdType="pmc">8514852</ArticleId><ArticleId IdType="doi">10.1016/j.bj.2021.06.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettinardi A, Brugnoni D, Quiròs-Roldan E, Malagoli A, La Grutta S, Correra A, et al. Missense mutations in the Fas Gene resulting in Autoimmune Lymphoproliferative Syndrome: a molecular and immunological analysis. Blood. 1997;89:902–9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V89.3.902</ArticleId></ArticleIdList></Reference><Reference><Citation>Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IAG, Debatin KM, Fischer A, et al. Mutations in Fas Associated with Human Lymphoproliferative Syndrome and Autoimmunity. Science. 1995;268:1347–9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.7539157</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasahara Y, Wada T, Niida Y, Yachie A, Seki H, Ishida Y, et al. Novel Fas (CD95/APO-1) mutations in infants with a lymphoproliferative disorder. Int Immunol. 1998;10:195–202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/10.2.195</ArticleId></ArticleIdList></Reference><Reference><Citation>Elgharbawy FM, Karim MY, Soliman DS, Hassan AS, Sudarsanan A, Gad A. Case report: neonatal autoimmune lymphoproliferative syndrome with a novel pathogenic homozygous FAS variant effectively treated with sirolimus. Front Pediatr. 2023;11:1150179.</Citation><ArticleIdList><ArticleId IdType="pmc">10159173</ArticleId><ArticleId IdType="doi">10.3389/fped.2023.1150179</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansford JR, Pal M, Poplawski N, Haan E, Boog B, Ferrante A, et al. In utero and early postnatal presentation of autoimmune lymphoproliferative syndrome in a family with a novel FAS mutation. Haematologica. 2013;98:e38.</Citation><ArticleIdList><ArticleId IdType="pmc">3659999</ArticleId><ArticleId IdType="doi">10.3324/haematol.2012.070524</ArticleId></ArticleIdList></Reference><Reference><Citation>Naveed M, Butt UBK, Mannan J. Autoimmune Lymphoproliferative Syndrome Neonatal Onset. 2014;24.</Citation></Reference><Reference><Citation>Kahwash SB, Fung B, Savelli S, Bleesing JJ, Qualman SJ. Autoimmune lymphoproliferative syndrome (ALPS): a case with congenital onset. Pediatr Dev Pathol. 2007;10:315–9.</Citation><ArticleIdList><ArticleId IdType="doi">10.2350/06-06-0105.1</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Burg M, de Groot R, Comans-Bitter WM, den Hollander JC, Hooijkaas H, Neijens HJ, et al. Autoimmune lymphoproliferative syndrome (ALPS) in a child from consanguineous parents: a dominant or recessive disease? Pediatr Res. 2000;47(3):336–43.</Citation></Reference><Reference><Citation>Chandramati J, Sidharthan N, Ponthenkandath S. Neonatal autoimmune lymphoproliferative syndrome: a case report and a brief review. J Pediatr Hematol Oncol. 2021;43(2):e227–e229.</Citation></Reference><Reference><Citation>Lai N, Liu L, Lin L, Cui C, Wang Y, Min Q, et al. Effective and safe treatment of a novel IL2RA deficiency with rapamycin. J Allergy Clin Immunol Pract. 2020;8:1132–e11354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaip.2019.09.027</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J, Luo Y, Li H, Zhao Y, Zhao J, Han X, et al. Deep immunophenotyping of human whole blood by standardized multi-parametric Flow cytometry analyses. Phenomics. 2023;3:309–28.</Citation><ArticleIdList><ArticleId IdType="pmc">10260734</ArticleId><ArticleId IdType="doi">10.1007/s43657-022-00092-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Wang W, Liu L, Hou J, Ying W, Hui X, et al. Report of a Chinese cohort with activated phosphoinositide 3-Kinase δ syndrome. J Clin Immunol. 2018;38:854–63.</Citation></Reference><Reference><Citation>Oliveira JB, Bleesing JJ, Dianzani U, Fleisher TA, Jaffe ES, Lenardo MJ et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood. 2010;116:e35–40.</Citation></Reference><Reference><Citation>Mahnke YD, Beddall MH, Roederer M. OMIP-013: differentiation of human T-cells. Cytometry A. 2012;81A:935–6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.22201</ArticleId></ArticleIdList></Reference><Reference><Citation>Staser KW, Eades W, Choi J, Karpova D, DiPersio JF. OMIP-042: 21-color flow cytometry to comprehensively immunophenotype major lymphocyte and myeloid subsets in human peripheral blood. Cytom Part J Int Soc Anal Cytol. 2018;93:186–9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.23303</ArticleId></ArticleIdList></Reference><Reference><Citation>Healy ZR, Murdoch DM. OMIP-036: co-inhibitory receptor (immune checkpoint) expression analysis in human T cell subsets. Cytometry A. 2016;89:889–92.</Citation><ArticleIdList><ArticleId IdType="pmc">5375024</ArticleId><ArticleId IdType="doi">10.1002/cyto.a.22938</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson IIPA, Seder RA. OMIP-067: 28-Color Flow Cytometry Panel to evaluate human T-Cell phenotype and function. Cytometry A. 2020;97:1032–6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.24189</ArticleId></ArticleIdList></Reference><Reference><Citation>Alpert A, Pickman Y, Leipold M, Rosenberg-Hasson Y, Ji X, Gaujoux R, et al. A clinically meaningful metric of immune age derived from high-dimensional longitudinal monitoring. Nat Med. 2019;25:487–95.</Citation><ArticleIdList><ArticleId IdType="pmc">6686855</ArticleId><ArticleId IdType="doi">10.1038/s41591-019-0381-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer BE, Blyveis N, Fontenot AP, Wilson CC. Functional and phenotypic characterization of CD57 + CD4 + T cells and Their Association with HIV-1-Induced T cell Dysfunction1. J Immunol. 2005;175:8415–23.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.175.12.8415</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedroza-Seres M, Linares M, Voorduin S, Enrique R, Lascurain R, Garfias Y, et al. Pars planitis is associated with an increased frequency of effector‐memory CD57 + T cells. Br J Ophthalmol. 2007;91:1393–8.</Citation><ArticleIdList><ArticleId IdType="pmc">2001003</ArticleId><ArticleId IdType="doi">10.1136/bjo.2007.116277</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahnke YD, Beddall MH, Roederer M. OMIP-017: human CD4 + helper T-cell subsets including follicular helper cells. Cytom Part J Int Soc Anal Cytol. 2013;83:439–40.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.22269</ArticleId></ArticleIdList></Reference><Reference><Citation>Biancotto A, Dagur PK, Fuchs JC, Langweiler M, McCoy JP. OMIP-004: In-Depth Characterization of Human T Regulatory Cells. Cytom Part J Int Soc Anal Cytol. 2012;81:15–6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.21158</ArticleId></ArticleIdList></Reference><Reference><Citation>Liechti T, Roederer M. OMIP-060: 30-Parameter Flow Cytometry Panel to Assess T Cell Effector Functions and Regulatory T Cells. Cytometry A. 2019;95:1129–34.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.23853</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahnke YD, Beddall MH, Roederer M. OMIP-015: human regulatory and activated T-cells without intracellular staining. Cytometry A. 2013;83A:179–81.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.22230</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdoch DM, Staats JS, Weinhold KJ. OMIP-006: Phenotypic Subset Analysis of Human T Regulatory Cells (Tregs) via Polychromatic Flow Cytometry. Cytometry. 2012;81:281–3.</Citation><ArticleIdList><ArticleId IdType="pmc">3352600</ArticleId><ArticleId IdType="doi">10.1002/cyto.a.22024</ArticleId></ArticleIdList></Reference><Reference><Citation>Park LM, Lannigan J, Jaimes MC. OMIP-069: forty-color full spectrum Flow Cytometry Panel for Deep Immunophenotyping of Major Cell subsets in Human Peripheral blood. Cytometry A. 2020;97:1044–51.</Citation><ArticleIdList><ArticleId IdType="pmc">8132182</ArticleId><ArticleId IdType="doi">10.1002/cyto.a.24213</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakhmanov M, Keller B, Gutenberger S, Foerster C, Hoenig M, Driessen G, et al. Circulating CD21low B cells in common variable immunodeficiency resemble tissue homing, innate-like B cells. Proc Natl Acad Sci U S A. 2009;106:13451–6.</Citation><ArticleIdList><ArticleId IdType="pmc">2726348</ArticleId><ArticleId IdType="doi">10.1073/pnas.0901984106</ArticleId></ArticleIdList></Reference><Reference><Citation>Golinski M-L, Demeules M, Derambure C, Riou G, Maho-Vaillant M, Boyer O, et al. CD11c+ B cells are mainly memory cells, precursors of antibody secreting cells in healthy donors. Front Immunol. 2020;11:32.</Citation></Reference><Reference><Citation>Min Q, Meng X, Zhou Q, Wang Y, Li Y, Lai N, et al. RAG1 splicing mutation causes enhanced B cell differentiation and autoantibody production. JCI Insight. 2021;6(19):e148887.</Citation></Reference><Reference><Citation>Szczawińska-Popłonyk A, Grześk E, Schwartzmann E, Materna-Kiryluk A, Małdyk J. Case Report: autoimmune lymphoproliferative syndrome vs. chronic active Epstein-Barr Virus infection in children: a diagnostic challenge. Front Pediatr. 2021;9:798959.</Citation><ArticleIdList><ArticleId IdType="pmc">8757380</ArticleId><ArticleId IdType="doi">10.3389/fped.2021.798959</ArticleId></ArticleIdList></Reference><Reference><Citation>Pace R, Vinh DC. Autoimmune lymphoproliferative syndrome and Epstein-Barr Virus-Associated Lymphoma: an adjunctive diagnostic role for monitoring EBV viremia? Case Rep Immunol. 2013;2013:245893.</Citation></Reference><Reference><Citation>Arkwright PD, Rieux-Laucat F, Le Deist F, Stevens RF, Angus B, Cant AJ. Cytomegalovirus infection in infants with autoimmune lymphoproliferative syndrome (ALPS). Clin Exp Immunol. 2000;121:353–7.</Citation><ArticleIdList><ArticleId IdType="pmc">1905690</ArticleId><ArticleId IdType="doi">10.1046/j.1365-2249.2000.01304.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Lisco A, Wong C-S, Price S, Ye P, Niemela J, Anderson M, et al. Paradoxical CD4 Lymphopenia in Autoimmune Lymphoproliferative Syndrome (ALPS). Front Immunol. 2019;10:1193.</Citation><ArticleIdList><ArticleId IdType="pmc">6549489</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2019.01193</ArticleId></ArticleIdList></Reference><Reference><Citation>Chun HJ, Zheng L, Ahmad M, Wang J, Speirs CK, Siegel RM, et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeciency. Nature. 2002;419(6905):395–99.</Citation></Reference><Reference><Citation>Crawford SE, Ramani S, Tate JE, Parashar UD, Svensson L, Hagbom M, et al. Rotavirus infection. Nat Rev Dis Primer. 2017;3:1–16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.83</ArticleId></ArticleIdList></Reference><Reference><Citation>De Francesco MA, Ianiro G, Monini M, Vezzoli C, Schumacher RF, Giliani S, et al. Persistent infection with Rotavirus Vaccine strain in severe combined immunodeficiency (SCID) child: is Rotavirus Vaccination in SCID Children a Janus Face? Vaccines. 2019;7:185.</Citation><ArticleIdList><ArticleId IdType="pmc">6963346</ArticleId><ArticleId IdType="doi">10.3390/vaccines7040185</ArticleId></ArticleIdList></Reference><Reference><Citation>De Bielke MGS, Perez L, Yancoski J, Oliveira JB, Danielian S. FAS haploinsufficiency caused by extracellular missense mutations underlying autoimmune lymphoproliferative syndrome. J Clin Immunol. 2015;35:769–76.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-015-0210-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Völkl S, Rensing-Ehl A, Allgäuer A, Schreiner E, Lorenz MR, Rohr J, et al. Hyperactive mTOR pathway promotes lymphoproliferation and abnormal differentiation in autoimmune lymphoproliferative syndrome. Blood. 2016;128:227–38.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2015-11-685024</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleiro D, Platanias LC. Intersection of mTOR and STAT signaling in immunity. Trends Immunol. 2015;36:21–9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2014.10.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, Wang S, Wang S, Xie J, Cui D. mTOR signaling: a pivotal player in Treg cell dysfunction in systemic lupus erythematosus. Clin Immunol. 2022;245:109153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2022.109153</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng H, Chi H. mTOR signaling in the differentiation and function of regulatory and effector T cells. Curr Opin Immunol. 2017;46:103–11.</Citation><ArticleIdList><ArticleId IdType="pmc">5554750</ArticleId><ArticleId IdType="doi">10.1016/j.coi.2017.04.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Rensing-Ehl A, Völkl S, Speckmann C, Lorenz MR, Ritter J, Janda A, et al. Abnormally differentiated CD4 + or CD8 + T cells with phenotypic and genetic features of double negative T cells in human Fas deficiency. Blood. 2014;124:851–60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2014-03-564286</ArticleId></ArticleIdList></Reference><Reference><Citation>Perl A, Morel L. Expanding scope of TEMRA in autoimmunity. EBioMedicine. 2023;90:104520.</Citation></Reference><Reference><Citation>Xiong H, Cui M, Kong N, Jing J, Xu Y, Liu X et al. Cytotoxic CD161-CD8+ TEMRA cells contribute to the pathogenesis of systemic lupus erythematosus. EBioMedicine. 2023;90:104507.</Citation></Reference><Reference><Citation>Nielsen BR, Ratzer R, Börnsen L, von Essen MR, Christensen JR, Sellebjerg F. Characterization of naïve, memory and effector T cells in progressive multiple sclerosis. J Neuroimmunol. 2017;310:17–25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2017.06.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer K, Voelkl S, Heymann J, Przybylski GK, Mondal K, Laumer M, et al. Isolation and characterization of human antigen-specific TCRαβ + CD4-CD8- double-negative regulatory T cells. Blood. 2005;105:2828–35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2004-07-2583</ArticleId></ArticleIdList></Reference><Reference><Citation>Voelkl S, Gary R, Mackensen A. Characterization of the immunoregulatory function of human TCR-αβ + CD4 – CD8 – double-negative T cells. Eur J Immunol. 2011;41:739–48.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201040982</ArticleId></ArticleIdList></Reference><Reference><Citation>Maccari ME, Fuchs S, Kury P, Andrieux G, Völkl S, Bengsch B, et al. A distinct CD38 + CD45RA + population of CD4+, CD8+, and double-negative T cells is controlled by FAS. J Exp Med. 2020;218:e20192191.</Citation><ArticleIdList><ArticleId IdType="pmc">7658692</ArticleId><ArticleId IdType="doi">10.1084/jem.20192191</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotty S. Follicular helper CD4 T cells (T <sub>FH</sub>). Annu Rev Immunol. 2011;29:621–63.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-031210-101400</ArticleId></ArticleIdList></Reference><Reference><Citation>Olatunde AC, Hale JS, Lamb TJ. Cytokine-skewed tfh cells: functional consequences for B cell help. Trends Immunol. 2021;42:536–50.</Citation><ArticleIdList><ArticleId IdType="pmc">9107098</ArticleId><ArticleId IdType="doi">10.1016/j.it.2021.04.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubtsov AV, Rubtsova K, Fischer A, Meehan RT, Gillis JZ, Kappler JW, et al. Toll-like receptor 7 (TLR7)–driven accumulation of a novel CD11c + B-cell population is important for the development of autoimmunity. Blood. 2011;118:1305–15.</Citation><ArticleIdList><ArticleId IdType="pmc">3152497</ArticleId><ArticleId IdType="doi">10.1182/blood-2011-01-331462</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Zhang Y, Han J, Yang M, Zhu J, Jin T. Transitional B cells involved in autoimmunity and their impact on neuroimmunological diseases. J Transl Med. 2020;18:131.</Citation><ArticleIdList><ArticleId IdType="pmc">7079408</ArticleId><ArticleId IdType="doi">10.1186/s12967-020-02289-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin W, Luo Z, Yang H, Peripheral B. Cell subsets in Autoimmune diseases: clinical implications and effects of B Cell-targeted therapies. J Immunol Res. 2020;2020:9518137.</Citation><ArticleIdList><ArticleId IdType="pmc">7125470</ArticleId><ArticleId IdType="doi">10.1155/2020/9518137</ArticleId></ArticleIdList></Reference><Reference><Citation>Landolt-Marticorena C, Wither R, Reich H, Herzenberg A, Scholey J, Gladman DD, et al. Increased expression of B cell activation factor supports the abnormal expansion of Transitional B cells in systemic Lupus Erythematosus. J Rheumatol. 2011;38:642–51.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.100214</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Wang W, Wu Q, Zhou Q, Ying W, Hui X, et al. Phenotypic and immunological characterization of patients with activated PI3Kδ syndrome 1 presenting with autoimmunity. J Clin Immunol. 2024;44:102.</Citation><ArticleIdList><ArticleId IdType="pmc">11026262</ArticleId><ArticleId IdType="doi">10.1007/s10875-024-01705-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks EG, Balk SP, Aupeix K, Colonna M, Strominger JL, Groh-Spies V. Human T-cell receptor (TCR) alpha/beta + CD4-CD8- T cells express oligoclonal TCRs, share junctional motifs across TCR V beta-gene families, and phenotypically resemble memory T cells. Proc Natl Acad Sci U S A. 1993;90:11787–91.</Citation><ArticleIdList><ArticleId IdType="pmc">48069</ArticleId><ArticleId IdType="doi">10.1073/pnas.90.24.11787</ArticleId></ArticleIdList></Reference><Reference><Citation>Bristeau-Leprince A, Mateo V, Lim A, Magerus-Chatinet A, Solary E, Fischer A, et al. Human TCR α/β + CD4 – CD8 – double-negative T cells in patients with autoimmune lymphoproliferative Syndrome Express restricted Vβ TCR diversity and are clonally related to CD8 + T Cells1. J Immunol. 2008;181:440–8.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.181.1.440</ArticleId></ArticleIdList></Reference><Reference><Citation>Hershberg U, Luning Prak ET. The analysis of clonal expansions in normal and autoimmune B cell repertoires. Philos Trans R Soc B Biol Sci. 2015;370:20140239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rstb.2014.0239</ArticleId></ArticleIdList></Reference><Reference><Citation>Teachey DT. New advances in the diagnosis and treatment of Autoimmune Lymphoproliferative Syndrome (ALPS). Curr Opin Pediatr. 2012;24:1–8.</Citation><ArticleIdList><ArticleId IdType="pmc">3673763</ArticleId><ArticleId IdType="doi">10.1097/MOP.0b013e32834ea739</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P, Huang P, Yang Y, Hao M, Peng H, Li F. Updated Understanding of Autoimmune Lymphoproliferative Syndrome (ALPS) Clinical Reviews in Allergy &amp; Immunology. 2016: 55–63.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>